NASDAQ$VXRT
Vaxart Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Vaxart reported first quarter 2024 financial results and provided a business update.
Vaxart announced positive topline results from its Phase 1 trial of an oral pill bivalent norovirus candidate focused on lactating mothers. They also anticipate initiating a Phase 2b study evaluating their XBB COVID-19 vaccine candidate as early as the second quarter of 2024.
- Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants
- Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator as early as the second quarter of 2024
- Anticipates meeting with the FDA in mid-2024 to evaluate clinical data and discuss next steps for its norovirus program
- Antibodies to norovirus rose on average 4.0 fold in response to the GI.1 virus strain and 6.0 fold in response to the GII.4 virus strain in the breastmilk of lactating mothers who received the Vaxart vaccine candidate in the high dose group.
Headline financials
Revenue & EPS history
Vaxart · Revenue · Quarterly
$2.18M
Forward guidance
Vaxart anticipates initiating the Phase 2b trial as early as the second quarter of 2024 and meeting with the FDA in mid-2024 to evaluate clinical data and discuss next steps for its norovirus program.
Tailwinds
- Positive results from Phase 1 norovirus study
- Potential of oral pill vaccine to protect infants
- Initiating Phase 2b study for XBB COVID-19 vaccine
- Meeting with the FDA to evaluate norovirus program
- Recent preclinical data suggests COVID-19 XBB construct showed a more robust immunogenic response
Headwinds
- Uncertainties inherent in research and development
- Risk of unfavorable new clinical data
- Clinical trial data are subject to differing interpretations
- Vaxart may not be able to obtain, maintain, and enforce necessary patent
- Vaxart's capital resources may be inadequate
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-1.4%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
37%
23 / 62 earnings
Positive
+22.7%
Q1 2024
Best reaction
-23.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | -8.8% | -19.5% | |
| Q4 2025 | -13.0% | -14.9% | -14.9% | |
| Q3 2025 | +11.6% | +5.4% | +0.0% | |
| Q1 2025 | -0.7% | +19.0% | +66.7% | |
| Q4 2024 | -9.1% | -19.3% | -40.4% | |
| Q3 2024 | -12.8% | -15.3% | -18.1% | |
| Q2 2024 | -2.7% | +0.0% | +48.3% | |
| Q1 2024 | +22.7% | +35.2% | +7.0% | |
| Q4 2023 | -4.4% | +2.7% | -19.5% | |
| Q3 2023 | +8.4% | +12.3% | +12.3% | |
| Q2 2023 | +1.3% | -3.9% | +9.2% | |
| Q1 2023 | +0.0% | +0.0% | +44.8% | |
| Q4 2022 | +0.0% | -10.1% | -16.5% | |
| Q3 2022 | -11.9% | +16.1% | -20.3% | |
| Q2 2022 | +3.4% | +1.2% | -31.1% | |
| Q1 2022 | -9.6% | -6.2% | +5.1% | |
| Q4 2021 | +18.9% | +12.8% | +13.9% | |
| Q3 2021 | -8.0% | -6.7% | -12.9% | |
| Q2 2021 | +5.4% | +11.6% | +4.9% | |
| Q1 2021 | -18.7% | -33.2% | -31.7% | |
| Q4 2020 | -2.6% | -2.7% | -18.4% | |
| Q3 2020 | +10.0% | +23.0% | +61.4% | |
| Q2 2020 | -4.9% | +11.3% | -49.0% | |
| Q1 2020 | +1.1% | -2.1% | -20.7% | |
| Q4 2019 | -23.1% | -27.4% | -15.0% | |
| Q3 2019 | -2.9% | -11.4% | -8.6% | |
| Q2 2019 | +21.1% | +17.5% | +22.8% | |
| Q1 2019 | +8.5% | +9.9% | -8.5% | |
| Q4 2018 | -9.5% | -12.2% | -25.3% | |
| Q3 2018 | -15.8% | -12.1% | +0.7% | |
| Q2 2018 | +0.6% | -1.0% | +0.3% | |
| Q1 2018 | -5.3% | -1.8% | +1.8% | |
| Q4 2017 | +4.8% | +0.0% | +9.5% | |
| Q3 2017 | -2.0% | +0.0% | -6.0% | |
| Q2 2017 | -1.7% | -1.7% | -46.6% | |
| Q1 2017 | -8.3% | -4.1% | -33.2% | |
| Q4 2016 | +0.0% | +11.3% | +12.0% | |
| Q3 2016 | -3.1% | — | — | |
| Q2 2016 | -15.2% | — | — | |
| Q1 2016 | +7.6% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -3.1% | — | — | |
| Q2 2015 | -2.4% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q3 2014 | -6.3% | — | — | |
| Q2 2014 | +0.2% | — | — | |
| Q1 2014 | +1.5% | — | — | |
| Q4 2013 | +1.5% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +2.6% | — | — | |
| Q1 2013 | +0.6% | — | — | |
| Q4 2012 | -1.8% | — | — | |
| Q3 2012 | +1.1% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -1.0% | — | — | |
| Q2 2010 | -5.2% | — | — | |
| Q2 2011 | -5.2% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q4 2010 | +2.0% | — | — | |
| Q3 2010 | +0.2% | — | — | |
| Q1 2010 | -7.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro